Ontology highlight
ABSTRACT: Background
Frunevetmab, a felinized antinerve growth factor monoclonal antibody, effectively decreases osteoarthritis (OA) pain in cats.Objective
To evaluate the efficacy of frunevetmab given at monthly intervals in a randomized, placebo-controlled, parallel-group, double-blind superiority study.Animals
Two hundred seventy-five client-owned cats with naturally-occurring OA pain and associated mobility impairment and disability.Methods
Randomized, placebo-controlled, parallel-group, double-blind, superiority study. Following screening, cats received frunevetmab (nominal dose of 1.0 mg/kg, SC [effective dose range of 1.0-2.8 mg/kg]) or placebo on days 0, 28, and 56. Outcome measures were owner questionnaires and veterinary physical and orthopedic evaluations a
SUBMITTER: Gruen ME
PROVIDER: S-EPMC8692178 | biostudies-literature | 2021 Nov
REPOSITORIES: biostudies-literature